# Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators

**Authors:** Shun Zhang, Rui Liu, Zhengjie Li, Tao Pan, Xudong Wen, Sona Frankova, Sona Frankova, Sona Frankova, Sona Frankova

PMC · DOI: 10.1371/journal.pone.0328952 · PLOS One · 2026-03-03

## TL;DR

A machine learning model predicts short-term mortality in severe cirrhosis patients using clinical indicators like INR and bilirubin.

## Contribution

An interpretable machine learning model for predicting mortality in severe cirrhosis using routine clinical data.

## Key findings

- The model includes eight significant predictors with an AUC of 0.846 in the training cohort.
- Subgroup analysis showed significant mortality variations across different INR ranges.
- Key factors include INR, creatinine, and bilirubin levels, highlighting their clinical importance.

## Abstract

The critical need for precise risk stratification in severe liver cirrhosis is underscored by its substantial 30-day mortality rates, demanding reliable tools to guide clinical interventions.

To establish a machine learning-driven prognostic model for short-term mortality prediction in decompensated cirrhosis through comprehensive analysis of critical care data.

This retrospective cohort study analyzed 1,044 carefully curated cases from the MIMIC-IV database, randomly divided into training (n = 740) and validation (n = 304) sets. We developed a machine learning model incorporating multidimensional clinical parameters, with rigorous evaluation and internal validation. Short-term survival was analyzed via bootstrap-validated Cox proportional hazards regression. Prognostic heterogeneity across international normalized ratio (INR)-based strata was examined.

The final prediction model incorporated eight significant predictors: age (OR 1.051, 95% CI 1.033–1.070), INR (OR 1.423, 95%CI 1.231–1.644), creatinine (OR 1.171, 95%CI 1.071–1.208), platelets (OR 0.995, 95%CI 0.993–0.997), white blood cell (OR 1.116, 95%CI 1.078–1.155), total bilirubin (OR 1.027, 95%CI 1.002–1.052), peptic ulcer (OR 0.336, 95%CI 0.134–0.845), and Aspartate Aminotransferase/Alanine Aminotransferase (AST/ALT) (OR 1.508, 95%CI 1.294–1.757). The model demonstrated excellent discrimination with an AUC of 0.846 in the training cohort. Cox regression analysis confirmed these findings and identified additional associations with aspartate aminotransferase and red blood cell levels. Furthermore, the indicators within the model provide accurate predictions for the clinical outcomes of patients suffering from severe cirrhosis. Subgroup analysis revealed significant mortality variations across different INR ranges (P < 0.001).

Our prediction model identifies high-risk cirrhotic patients and highlights critical prognostic factors, offering clinicians a valuable tool for risk stratification and timely intervention. The strong correlation between laboratory markers, complications, and outcomes underscores the importance of close monitoring in this population. However, our model is an initial step, effective within the ICU but requiring external, multi-center studies to broaden its clinical applicability, which is a clear priority for our future work.

## Linked entities

- **Diseases:** cirrhosis (MONDO:0005155), peptic ulcer (MONDO:0004247)

## Full-text entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CETN2 (centrin 2) [NCBI Gene 1069] {aka CALT, CEN2}, THPO (thrombopoietin) [NCBI Gene 7066] {aka CAMT2, MGDF, MKCSF, ML, MPLLG, THC9}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}
- **Diseases:** peptic ulcer hemorrhage (MESH:D010438), gastric mucosal congestion (MESH:D013272), bacterial infections (MESH:D001424), alcohol-related liver disease (MESH:D008108), congestive heart failure (MESH:D006333), Renal disease (MESH:D007674), hepatocellular damage and dysfunction (MESH:D056486), dementia (MESH:D003704), hepatic encephalopathy (MESH:D006501), fibrotic livers (MESH:D017093), cardiac and renal (MESH:D006331), hyperbilirubinemia (MESH:D006932), platelet destruction (MESH:D008105), HPS (MESH:D020065), chronic pulmonary disease (MESH:D002908), sepsis (MESH:D018805), PHT (MESH:D006976), ascites (MESH:D001201), Portal hypertension (MESH:D006975), thrombosis (MESH:D013927), Chronic Liver Failure - Organ Failure (MESH:D058625), ACLF (MESH:D065290), endotoxemia (MESH:D019446), PoPH (MESH:D006973), Mortality (MESH:D003643), hypersplenism (MESH:D006971), alcoholic and non-alcoholic liver cirrhosis (MESH:D008104), myocardial infarction (MESH:D009203), coagulation dysfunction (MESH:D001778), infected (MESH:D007239), end-stage cirrhosis (MESH:D007676), Thrombocytopenia (MESH:D013921), cholestasis (MESH:D002779), Peptic Ulcer (MESH:D010437), end-organ damage (MESH:C564816), alcohol-associated hepatitis (MESH:D006519), cerebrovascular disease (MESH:D002561), vitamin K deficiency (MESH:D014813), acute liver decompensation (MESH:D017114), respiratory, neurological, and coagulation disorders (MESH:D025861), advanced (MESH:D020178), hypovolemia (MESH:D020896), leukocytosis (MESH:D007964), bleeding ulcers (MESH:D014456), multiple organ failure (MESH:D009102), bleeding (MESH:D006470), function (MESH:D003291), paralysis (MESH:D010243), acute kidney injury (MESH:D058186), hypoalbuminemia (MESH:D034141), postrenal obstruction (MESH:D000402), haemolysis (MESH:D006461), frailty (MESH:D000073496), hypoxemia (MESH:D000860), APS (MESH:D016884), inflammation (MESH:D007249), chronic liver disease (MESH:D008107), Cirrhosis (MESH:D005355), peripheral vascular disease (MESH:D016491), esophagogastric variceal bleeding (MESH:D014648)
- **Chemicals:** alcohol (MESH:D000438), creatinine (MESH:D003404), PONE-D-25-36378 (-), sodium (MESH:D012964), aspirin (MESH:D001241), Bilirubin (MESH:D001663)
- **Species:** Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956121/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956121/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956121/full.md

---
Source: https://tomesphere.com/paper/PMC12956121